Arrayus Technologies Awarded Funding to Advance Focused Ultrasound Therapy through AI
TORONTO, Jan. 18, 2023 /CNW/ - Arrayus Technologies Inc., an innovator in focused ultrasound therapy for oncology, announced today it has been awarded funding of up to $1.9 million from INOVAIT and the Government of Canada through the INOVAIT Focus Fund to develop and integrate machine learning and artificial intelligence capabilities into its therapy platform.
Arrayus, a clinical-stage medical technology company, has developed a versatile focused ultrasound device that uses the energy of targeted ultrasound waves to destroy tissue and produce other biological effects deep in the body without making any incisions. The company is pursuing the non-invasive surgical treatment of uterine fibroids, a benign uterine tumor, as its first clinical indication. Future indications include treatment of pancreas, liver and kidney cancers.
Built using a novel ultrasound array design, Arrayus' focused ultrasound therapy platform is the field's most technologically advanced. In contrast to existing systems which treat point by point, Arrayus' device is the only system that provides physicians with temporal and spatial control of the complete treatment field using 6144 individually controlled ultrasound transducer elements. The company believes this will offer both patients and providers significant advantages, including faster, safer treatments and expanded patient eligibility.
With the funding contribution from the INOVAIT focus fund, and in collaboration with Sunnybrook Research Institute and Vancouver Coastal Health, Arrayus will use machine learning and automation tools to develop AI-enhanced treatment planning and control algorithms for focused ultrasound therapy. he resulting innovations will be incorporated into the company's flagship product where they are expected to improve patient experience, shorten physician training time and learning curve, and decrease procedure times by up to 75% compared to existing commercial systems.
"Focused ultrasound therapy has the ability to radically improve the way cancer is treated", said James O'Reilly, Arrayus' chief executive officer. "This investment will enable us to integrate cutting-edge machine learning tools to unlock the full potential of this technology and help position Arrayus as a global leader in this rapidly growing field".
The Arrayus Technologies' MR-guided focused ultrasound platform is not commercially available and is currently limited to investigational use in approved clinical studies.
About Arrayus Technologies
About Sunnybrook Research Institute
SOURCE Arrayus Technologies Inc.